Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series: World’s leading Event Organizer
Virotherapy is a process of treatment by converting viruses into therapeutic agents by reprogramming viruses to treat diseases using biotechnology. Virotherapy are classified into: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy. Virotherapy can also define in broadly to the use of viruses to treat certain medical conditions by killing pathogens.
Viral Gene Therapy
Viral gene therapy most commonly uses non-replicating viruses to convey therapeutic genes to cells with genetic malfunctions. At earlier faces considerable delays due to safety issues as the uncontrolled delivery of a gene into a host genome has the potential to disrupt tumor suppressing genes and induce cancer, and did so in two cases. Immune responses to viral therapies also pretense a barrier to successful treatment, for this reason eye therapy for genetic blindness is attractive as the eye is an immune privileged site, preventing an immune response.
Oncolytic Virotherapy is not a new idea – as early as the mid 1950s doctors were observing that cancer patients who suffered a non-related viral infection, or who had been vaccinated recently, showed signs of improvement, this has been largely attributed to the production of interferon and tumour necrosis factors in response to viral infection, but Oncolytic viruses are being designed that selectively target and lyse only cancerous cells.
Viral immunotherapy uses viruses to introduce specific antigens to the patient's immune system. Unlike traditional vaccines, in which weakened or killed virus/bacteria is used to produce an immune response, viral immunotherapy uses genetically engineered viruses to present a specific antigen to the immune system. That antigen could be from any species of virus/bactera or even human disease antigens, for example cancer antigens.
OMICS Group hosts over 400 leading-edge peer reviewed Open Access Journals and organize over 300 International Conferences annually all over the world. OMICS Publishing Group journals have over 3 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 30000 eminent personalities that ensure a rapid, quality and quick review process. OMICS Group signed an agreement with more than 500 International Societies to make healthcare information Open Access.
This page will be updated regularly.
This page was last updated on 13th Oct, 2014
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising